161 related articles for article (PubMed ID: 32808809)
21. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.
Suzuki R; Wei X; Allen PK; Cox JD; Komaki R; Lin SH
Clin Lung Cancer; 2019 Mar; 20(2):117-123. PubMed ID: 30611672
[TBL] [Abstract][Full Text] [Related]
22. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
Liu D; Jin J; Zhang L; Li L; Song J; Li W
Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
[TBL] [Abstract][Full Text] [Related]
23. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
Sert F; Cosgun G; Yalman D; Ozkok S
Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
[TBL] [Abstract][Full Text] [Related]
24. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
25. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
[TBL] [Abstract][Full Text] [Related]
26. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
[TBL] [Abstract][Full Text] [Related]
27. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
[TBL] [Abstract][Full Text] [Related]
28. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
29. Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer.
Cheng H; Bhushan S; Li N; Xiao Z; Gao K
J Cancer Res Ther; 2022; 18(6):1666-1673. PubMed ID: 36412428
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
Gu X; Sun S; Gao XS; Xiong W; Qin S; Qi X; Ma M; Li X; Zhou D; Wang W; Yu H
Sci Rep; 2016 Mar; 6():23893. PubMed ID: 27025911
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.
Zhang Y; Jiang C; Li J; Sun J; Qu X
Clin Transl Oncol; 2015 Oct; 17(10):810-8. PubMed ID: 26077119
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC.
Guo M; Li W; Li B; Zou B; Wang S; Meng X; Sun X; Yu J; Wang L
Int Immunopharmacol; 2019 Jul; 72():395-401. PubMed ID: 31030095
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer.
Zhu M; Feng M; He F; Han B; Ma K; Zeng X; Liu Z; Liu X; Li J; Cao H; Liang Y; Jia C; Zhang L
Clin Chim Acta; 2018 Aug; 483():296-302. PubMed ID: 29758203
[TBL] [Abstract][Full Text] [Related]
34. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Yao Y; Yuan D; Liu H; Gu X; Song Y
Cancer Immunol Immunother; 2013 Mar; 62(3):471-9. PubMed ID: 22986452
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma.
Li Y; Li H; Li W; Wang L; Yan Z; Yao Y; Yao R; Xu K; Li Z
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27925303
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
40. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.
Lan H; Zhou L; Chi D; Zhou Q; Tang X; Zhu D; Yue J; Liu B
Oncotarget; 2017 May; 8(21):35301-35310. PubMed ID: 27845912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
